ArticleFrontiers in public health2025
Global health inequities in retinoblastoma: a 1990-2021 analysis across socio-demographic index regions.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cross-national inequalities and public health policy effects of the global retinoblastoma burden from 1990 to 2021 and projections to 2035.Frontiers in public health · 2026Article
- Global burden of hemolytic disease and neonatal jaundice from 1990 to 2021 with projections to 2050: a systematic analysis of the GBD 2021 data.BMC pediatrics · 2025Article
- Circular RNAs and immunotherapy in retinoblastoma: emerging biomarkers and precision therapeutic strategies.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess health inequities associated with retinoblastoma across various Socio-Demographic Index (SDI) regions and evaluate whether these inequities have decreased from 1990 to 2021, with the aim of enhancing awareness and guiding government policies. Design: Population-based demographic analysis. Participants: Children diagnosed with retinoblastoma from 204 countries and territories. Methods: The estimates and their 95% uncertainty interval (UI) for disability-adjusted life-years (DALYs) of retinoblastoma were extracted from Global Burden of Disease study (GBD) 2021. The age-standardized DALYs and the average annual percentage change (AAPC) were evaluated. Main measures: The Slope Index of Inequality (SII) and concentration index were computed to quantify the absolute and relative cross-national health inequality. Results: All SDI regions and the majority of countries experienced a significant decline in age-standardized DALYs from 1990 to 2021. The decrease was more rapid in middle to high SDI regions than in low to low-middle SDI regions. Globally, the 2-4 years age group had the highest DALYs rate, consistent with trends in low to middle SDI regions. In contrast, the highest DALYs rate in high and high-middle SDI regions was found in the 12-23 months age group. The SII was -40.81 (95% CI -36.04 to -45.58) DALYs per 100,000 population in 1990 and - 30.32 (95% CI -27.18 to -33.47) DALYs per 100,000 population in 2021. The concentration index increased from -0.37 (95% CI -0.46 to -0.28) in 1990 to -0.45 (95% CI -0.53 to -0.36) in 2021, although this increase did not reach statistical significance ( Conclusion: Despite advancements in retinoblastoma management, the overall burden of the disease-related DALY remains disproportionately concentrated in poorer populations. The health inequalities are persisting and widening. This underscores the limitations of current efforts. Until progress benefits everyone, the vision of equitable healthcare remains imperfect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.